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Abstract
Background: Human papillomavirus (HPV) is the causative agent in cervical cancer and HPV genotypes 16 and 18
cause the majority of these cancers. Natural killer (NK) cells destroy virally infected and tumour cells via killer
immunoglobulin-like receptors (KIR) that recognize decreased MHC class I expression. These NK cells may contribute
to clearance of HPV infected and/or dysplastic cells, however since KIR controls NK cell activity, KIR gene variation
may determine outcome of infection.
Methods: KIR gene frequencies were compared between 147 patients with a history of high-grade cervical
intraepithelial neoplasia (CIN) and a control population of 187, to determine if any KIR genes are associated with
high-grade CIN. In addition a comparison was also made between cases of high grade CIN derived from 30
patients infected with HPV 16/18 and 29 patients infected with non-16/18 HPV to determine if KIR variation
contributes to the disproportional carcinogenesis derived from HPV 16/18 infection.
Results: High-grade CIN was weakly associated with the absence of KIR2DL2 and KIR2DS2 (p = 0.046 and 0.049
respectively, OR 0.6; 95% CI 0.4 – 0.9) but this association was lost after correction for multi-gene statistical analysis.
No difference in KIR gene frequencies was found between high-grade CIN caused by HPV 16/18 and non-16/18.
Conclusion: No strong association between KIR genes, high-grade CIN and HPV genotype was found in the
Western Australian population.
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Background
Cervical cancer is the second most prevalent cancer in
women worldwide accounting for approximately 230 000
deaths each year and Human Papillomavirus (HPV) is the
causative agent [1]. HPV genotypes 16 and 18 cause the
majority of cancers and it was reported that approximately
80% of cervical cancers and 50% of high-grade pre-
cancerous lesions in Western Australia are caused by
these two genotypes [2]. Progression to cancer is preceded
by pre-cancerous lesions; the majority of low-grade le-
sions, cervical intraepithelial neoplasia 1 (CIN 1) regress
spontaneously, while high-grade lesions (CIN 2 and CIN 3)
often persist and may progress to cancer [3,4]. It is
thought that the immunological response may affect the
progression of cervical lesions and in particular, that nat-
ural killer (NK) cells may play a role in preventing disease
development [5-8].
Many viruses commonly down-regulate major histocom-
patibility complex (MHC) class I molecule expression to
avoid cytotoxic T cell responses and the down-regulation of
MHC class I molecules has been a common finding in cer-
vical cancer [9-12]. It has been found that the HPV E5 gene
encodes a protein that causes the alkalinisation of the golgi
apparatus and endosomes inducing the retention of MHC
class I complexes, thereby preventing their transport to the
cell surface [13]. It has also been reported that the HPV E7
gene codes for a protein that interrupts the synthesis of
MHC class I molecules [14].
NK cells are cytotoxic lymphocytes which kill target
cells with decreased MHC class I molecule expression as
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a defence mechanism against malignant transformation or
viral infection [15,16]. Previous studies which have investi-
gated the influence of NK cells in CIN development have
suggested a protective role of NK cells. An early report
found defective NK cell lysis of HPV 16 infected kera-
tinocytes in patients with CIN or cancer [17]. In another
study NK cells isolated from patients with advanced cer-
vical cancer demonstrated lower levels of cytotoxicity
against the human erythroleukaemia K562 cell line than
NK cells from women without cervical cancer suggesting
that NK cell activity was inversely correlated with severity
of disease [7]. Human NK cell activity is controlled by the
expression of activating and inhibitory receptors which
recognise ubiquitously expressed MHC class I molecules.
Killer immunoglobulin-like receptors (KIR) are genetically
highly polymorphic and recognize polymorphic HLA epi-
topes [18]. The KIR gene family is found on chromosome
19 and encodes receptors with either two (2D) or three
(3D) extracellular immunoglobulin-like domains. Inhibi-
tory receptors possess a long (L) cytoplasmic tail and
activating receptors possess a short (S) cytoplasmic tail
[19,20]. Individuals inherit different numbers and types of
KIR genes [21]. Generally, the KIR3D receptors recognise
HLA-A and HLA-B alleles, while KIR2D receptors recog-
nise HLA-C alleles [22]. KIR diversity has been driven by
rapid evolution to a variety of forces including response to
pathogens [20]. While determining genetic links to cer-
vical cancer have been elusive [23] recent studies have
suggested an association between KIR gene repertoire and
cervical cancer [24,25], however these studies examined
different populations (US/Costa Rica and Sweden) and
reported associations with different KIR genes.
The current study was undertaken to determine whether
there are any associations between KIR genes and high-
grade cervical intraepithelial neoplasia (CIN2 & 3), the
precursor to cervical cancer, in the Western Australian
population. Since 80% of cervical cancers in Western
Australia are caused by HPV 16 and 18 genotypes (HPV
16/18), we performed a separate analysis of high-grade
CIN samples containing these genotypes on the basis that
neoplasia derived from these may be especially resistant to
NK cell killing.
Results
KIR genotyping was successfully performed on all cervical
cytology specimens. Figure 1 show that the band intensity
of PCR products from DNA templates extracted from
cytological cervical ThinPrep samples in lanes 3 and 4
were comparable to those of the standards in lanes 1 and
2 which were extracted from cell lines (Figure 1).
All the KIR genes were represented in both the high
grade CIN cases and controls. Table 1 compares the
Figure 1 Examples of KIR genotyping results using cervical cytology samples. The KIR genotyping result for each sample was determined by
comparing the band sizes to the molecular weight marker. For Group 1, Group 2, Group 3 and Group 4; lanes 1 and 2 are JBUSH and CB6B genomic
DNA positive controls respectively, lanes 3 and 4 are the KIR PCR products from DNA extracts of cervical cytology specimens and lane 5 is the negative
control. Lane M is the molecular weight marker. Clear PCR products for KIR typing were achieved with cervical cytology samples seen in lanes 3 and 4.
Brestovac et al. Infectious Agents and Cancer 2013, 8:33 Page 2 of 5
http://www.infectagentscancer.com/content/8/1/33
frequencies of each KIR gene in cases and controls.
KIR2DL2 and KIR2DS2 frequencies were significantly
decreased in the high-grade CIN cases compared to the
controls (p = 0.046 and 0.049 respectively, OR 0.6; 95%
CI 0.6 – 0.9). However, significance was lost after
Bonferroni correction (p = 0.644 and p = 0.686, respect-
ively). No statistically significant differences were found
for any of the remaining KIR gene frequencies. There
was also no significant difference between patients and
controls for the total numbers of either activating or in-
hibitory KIR (activating p = 0.47, inhibitory p = 0.45),
nor any significant differences in any KIR gene frequen-
cies between the high grade CIN samples derived from
HPV 16/18 infection and those that were derived from
non-16/18 infection (Table 2).
Discussion
Risk factors which determine susceptibility to HPV infec-
tion and progression to cervical cancer are likely to be im-
munogenetic [8,23] and this is supported by the high
prevalence of cervical lesions in immunosuppressed pa-
tients [6]. Population-based studies in the United States
and in Costa Rica reported KIR3DS1 to be associated with
an increased risk for developing high-grade CIN or cer-
vical cancer, however they only considered CIN 3 as high-
grade and CIN 2 was not included [24]. In the current
study, there was no significant difference between the con-
trol and cases in KIR3DS1 frequency. Also, in this study
both CIN 2 and 3 were considered as high-grade CIN.
Arnheim et al. [25] did not find any single gene to be asso-
ciated with CIN but found that a genotype comprising
only KIR2DL1, KIR2DL2, KIR2DL3, KIR2DL4, KIR3DL1,
KIR3DL2, KIR3DL3 and KIR2DS4 was associated with an
increased risk of developing CIN. The same study reported
that KIR2DL5 was decreased in patients with CIN. How-
ever this previous study was based on all stages of CIN, and
it is known that the majority of low-grade lesions (CIN1)
regress spontaneously [2,4,26]. The inclusion of low-grade
lesions in any study as a precursor to cervical cancer re-
mains controversial [26]. In the current study no associ-
ation with high-grade CIN (CIN 2 & 3) was found with
KIR3DS1 or KIR2DL5. Indeed the frequency of these two
genes was virtually identical in patients and controls
(Table 1). We also did not find any cases or controls with a
genotype comprising only KIR2DL1, KIR2DL2, KIR2DL3,
KIR2DL4, KIR3DL1, KIR3DL2, KIR3DL3 and KIR2DS4 as
reported by Arnheim et al. [25]. Such a genotype which in-
cludes KIR2DL2 and not KIR2DS2 would be very rare in
any population as these two genes are usually in complete
linkage disequilibrium [27]. The only association found in
the current study was a protective effect of KIR2DL2 and
KIR2DS2 which was not significant after correction for
multiple gene analysis. This finding does not support the
study of Carrington et al. [24] in which these two genes
were more prevalent in cases than controls, though not
significantly so.
Table 1 Distribution of KIR genes in the Busselton control
population and the group of Western Australian women






correctedbn = 147 n = 187
2DL1 144 (98.0%) 178 (94.2%) 0.149 1
2DL2 67 (45.6%) 108 (57.1%) 0.046* 0.644
2DL3 136 (92.5%) 170 (89.9%) 0.531 1
2DL4 147 (100%) 189 (100%) 1 1
2DL5 78 (53.1%) 100 (52.9%) 0.978 1
3DL1 133 (90.5%) 177 (93.7%) 0.382 1
3DL2 147 (100%) 189 (100%) 1 1
3DL3 147 (100%) 189 (100%) 1 1
2DS1 58 (39.5%) 76 (40.2%) 0.978 1
2DS2 68 (46.3%) 109 (57.7%) 0.049* 0.686
2DS3 44 (29.9%) 55 (29.1%) 0.964 1
2DS4** 55 (37.4%) 77 (40.7%) 0.612 1
2DS5 50 (34.0%) 57 (30.2%) 0.526 1
3DS1 61 (41.5%) 78 (41.3%) 0.967 1
CIN, Cervical intraepithelial neoplasia; KIR, Killer immunoglobulin-like receptor.
aχ2 test with Yates correction was performed; p-values < 0.05 are indicated in
bold for χ2 test.
bCorrected p-values were determined by adjusting p-values for multi-gene
analysis using Bonferroni’s correction.
*OR = 0.6; 95% CI 0.4 – 0.9.
**2DS4 psuedogenes not counted.
Table 2 Distribution of KIR genes in HPV 16/18 and non
16/18 derived high grade CIN
KIR
gene
HPV 16/18 Non 16/18 p-
valuean = 30 n = 29
2DL1 28 (93%) 27 (93%) 0.97
2DL2 12 (40%) 16 (55%) 0.36
2DL3 23 (74%) 21 (72%) 0.87
2DL4 30 (100%) 29 (100%) 1
2DL5 12 (39%) 17 (59%) 0.20
3DL1 29 (96%) 24 (83%) 0.10
3DL2 30 (100%) 29 (100%) 1
3DL3 30 (100%) 29 (100%) 1
2DS1 12 (39%) 14 (48%) 0.63
2DS2 15 (48%) 18 (62%) 0.42
2DS3 7 (22%) 6 (21%) 0.86
2DS4 25 (81%) 21 (72%) 0.65
2DS5 12 (39%) 13 (45%) 0.83
3DS1 12 (39%) 13 (45%) 0.83
HPV, Human Papillomavirus; KIR, Killer immunoglobulin-like receptor.
aχ2 test with Yates correction was performed; p-values < 0.05 for significance.
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Although HPV 16 and 18 cause the majority of cervical
cancers in Western Australia, this study found no statistical
significant difference in any KIR gene frequency between
HPV 16/18 and non-16/18 derived high grade CIN. The
protective effect of KIR2DL2 and KIR2DS2 was not more
pronounced in the cases that were positive for the more
oncogenic HPV 16/18 types of virus. However, since HPV
has been associated with some head and neck cancers [28],
and the pathogenesis for these cancers is different, there
would be value in examining the association between these
and KIR.
Conclusion
This study found no strong association between KIR gene
frequencies and high-grade CIN in the Western Australian
population, although KIR2DL2 and KIR2DS2 may have a
very mild protective role against progression to high grade
CIN. No association between KIR gene frequencies and
HPV 16/18 derived high grade CIN was found.
Methods
Study population
Cervical cytology specimens in ThinPrep (Cytyc,
Boxborough, MA) methanol-based fixative, were col-
lected between December 2007 and August 2008 from
Western Diagnostics Pathology Laboratory, Perth,
Western Australia. The study population consisted of
147 women from Western Australia who had previously
been diagnosed with high-grade CIN. This test group
had a mean age of 38 with a range of 19 – 71 years. The
control frequencies for KIR genes were obtained from
187 women from the Busselton Health Study (BHS)
(http://bsn.uwa.edu.au/) population which is considered
to be reflective of the Western Australian population.
This control group had a mean age of 50 with a range of
19 – 88 years. Although CIN status was not obtained
for this control group high-grade CIN occurs very rarely
[29] and so would not impact on the statistics. Power
calculations indicate that this study had approximately
80% power to detect an odds ratio (OR) of less than 0.5
or greater than 2.0. High-grade CIN ThinPrep samples,
for which the HPV genotype had previously been deter-
mined by PCR and DNA sequencing in the L1 region
[2], were further grouped into those derived from HPV
16/18 (n = 30) infections and those from non-16/18 (n =
29). This study was approved by the Human Research
Ethics Committee at Curtin University of Technology (ap-
proval number SoBS08/07).
DNA extraction and PCR
Genomic DNA was extracted from cytology specimens by
a modified EDNA HiSpEx™ tissue kit (Saturn Biotech,
Perth, Australia) method in which ThinPrep cervical sam-
ples were mixed by shaking and inversion, a 500 μl aliquot
was removed and mixed with 1 mL of PCR grade water in
a microfuge tube. This was centrifuged at 14,000 RPM for
5 minutes and all traces of the supernatant removed from
the pellet. The pellet was then processed according to the
manufactures protocol. It is recognized that cells containing
integrated HPV would have genomic alterations; however
the majority of cells within the ThinPrep sample would not
be infected with HPV and would have normal genomes,
and so were considered suitable for KIR typing by PCR.
KIR genotyping was performed on all samples using
multiplexed amplification primers specific for the follow-
ing KIR genes: 2DL1, 2DL2, 2DL3, 2DL4, 2DL5, 2DS1,
2DS2, 2DS3, 2DS4, 2DS5, 3DL1, 3DL2, 3DL3 and 3DS1 as
described by Sun et al. [29]. In each typing run 10th Inter-
national Histocompatibility Workshop cell lines, CB6B
and JBUSH, were used as positive controls [30]. PCR
products were electrophoresed on a 2% agarose gel in
1× TAE buffer precast in SYBR Safe (Invitrogen, Carlsbad,
CA) and photographed under a UV transilluminator.
Statistical analysis
KIR gene frequencies in high grade CIN cases and con-
trols, and in HPV 16/18 and non 16/18 derived high grade
CIN, were compared by χ2 analysis with Yates’ correction.
A p-value less than 0.05 determined significance. Any p
values less than 0.05 were corrected for multi-gene statis-
tical analysis using Bonferroni’s correction [31].
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